Table 3.
Multivariable-Adjusted HRs for 1,25-Dihydroxyvitamin D Levels (overall, and stratified by 25-hydroxyvitamin D insufficiency) and Event-Free, Lymphoma-Specific, and Overall Survival
| 1,25-Dihydroxyvitamin D level (pg/mL) | No. | Event-Free Survival |
Lymphoma-Specific Survival |
Overall Survival |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Events | % Events | HR | 95% CI | No. of Events | % Events | HR | 95% CI | No. of Events | % Events | HR | 95% CI | ||
| DLBCL, all | |||||||||||||
| Q4 (62+) | 91 | 19 | 20.9 | 1.00 | Reference | 11 | 12.1 | 1.00 | Reference | 12 | 13.2 | 1.00 | Reference |
| Q3 (46–61) | 98 | 35 | 35.7 | 1.86 | 1.06 to 3.26 | 26 | 26.5 | 2.42 | 1.19 to 4.92 | 30 | 30.6 | 2.61 | 1.33 to 5.11 |
| Q2 (34–45) | 86 | 35 | 40.7 | 2.22 | 1.27 to 3.90 | 25 | 29.1 | 2.63 | 1.29 to 5.37 | 28 | 32.6 | 2.73 | 1.38 to 5.40 |
| Q1 (<34) | 92 | 43 | 46.7 | 2.18 | 1.26 to 3.76 | 28 | 30.4 | 2.16 | 1.07 to 4.37 | 30 | 32.6 | 2.14 | 1.09 to 4.21 |
| P for trend | .01 | .10 | .11 | ||||||||||
| DLBCL, insufficient 25-hydroxyvitamin D | |||||||||||||
| Q4 (62+) | 40 | 11 | 27.5 | 1.00 | Reference | 7 | 17.5 | 1.00 | Reference | 8 | 20.0 | 1.00 | Reference |
| Q3 (46–61) | 46 | 19 | 41.3 | 1.74 | 0.83 to 3.65 | 15 | 32.6 | 2.44 | 0.99 to 6.01 | 17 | 37.0 | 2.42 | 1.04 to 5.63 |
| Q2 (34–45) | 50 | 23 | 46.0 | 2.00 | 0.97 to 4.10 | 19 | 38.0 | 2.50 | 1.05 to 5.96 | 21 | 42.0 | 2.44 | 1.08 to 5.53 |
| Q1 (<34) | 54 | 29 | 53.7 | 1.95 | 0.96 to 3.97 | 22 | 40.7 | 1.99 | 0.84 to 4.71 | 23 | 42.6 | 1.88 | 0.83 to 4.26 |
| P for trend | .11 | .33 | .36 | ||||||||||
| DLBCL, sufficient 25-hydroxyvitamin D | |||||||||||||
| Q4 (62+) | 51 | 8 | 15.7 | 1.00 | Reference | 4 | 7.8 | 1.00 | Reference | 4 | 7.8 | 1.00 | Reference |
| Q3 (46–61) | 52 | 16 | 30.8 | 2.07 | 0.88 to 4.91 | 11 | 21.1 | 2.81 | 0.88 to 9.02 | 13 | 25.0 | 3.40 | 1.09 to 10.59 |
| Q2 (34–45) | 36 | 12 | 33.3 | 2.10 | 0.84 to 5.24 | 6 | 16.7 | 1.77 | 0.47 to 6.64 | 7 | 19.4 | 2.23 | 0.62 to 7.95 |
| Q1 (<34) | 38 | 14 | 36.8 | 2.32 | 0.93 to 5.34 | 6 | 15.8 | 1.66 | 0.47 to 5.93 | 7 | 18.4 | 1.92 | 0.56 to 6.58 |
| P for trend | .17 | .73 | .62 | ||||||||||
| TCL, all | |||||||||||||
| Median+ (46+) | 36 | 22 | 61.1 | 1.00 | Reference | 11 | 30.6 | 1.00 | Reference | 11 | 30.6 | 1.00 | Reference |
| < median (< 46) | 34 | 27 | 79.4 | 1.62 | 0.92 to 2.88 | 17 | 50.0 | 1.83 | 0.86 to 3.93 | 18 | 52.9 | 1.94 | 0.91 to 4.12 |
| P | .09 | .12 | .08 | ||||||||||
| TCL, insufficient 25-hydroxyvitamin D | |||||||||||||
| Median+ (46+) | 16 | 13 | 81.3 | 1.00 | Reference | 7 | 43.8 | 1.00 | Reference | 7 | 43.8 | 1.00 | Reference |
| < median (< 46) | 24 | 20 | 83.3 | 2.07 | 0.93 to 4.62 | 13 | 54.2 | 1.84 | 0.70 to 4.85 | 14 | 58.3 | 1.95 | 0.75 to 5.05 |
| P | .08 | .22 | .17 | ||||||||||
| TCL, sufficient 25-hydroxyvitamin D | |||||||||||||
| Median+ (46+) | 20 | 9 | 45.0 | 1.00 | Reference | 4 | 20.0 | 1.00 | Reference | 4 | 20.0 | 1.00 | Reference |
| < median (< 46) | 10 | 7 | 70.0 | 1.10 | 0.40 to 3.01 | 4 | 40.0 | 1.82 | 0.45 to 7.36 | 4 | 40.0 | 1.82 | 0.45 to 7.36 |
| P | .86 | .40 | .40 | ||||||||||
NOTE. Adjusted for International Prognostic Index. Quartile distribution based on histology specific cut points.
Abbreviations: HR, hazard ratio; DLBCL, diffuse large B-cell lymphoma; Q, quartile; TCL, T-cell lymphoma.